woman prepares an IV Drip

Derazantinib Effective for Patients With Some Types of Cholangiocarcinoma

Derazantinib treatment is effective and leads to durable objective responses in patients with inoperable or advanced intrahepatic cholangiocarcinoma with FGFR2 gene fusions or rearrangements, according to primary results from a phase 2 clinical trial called FIDES-01. These findings were presented on September 16, 2021, by Michele Droz Dit Busset, MD, at the European Society for…

Next post in CCA News Briefs